GSK’s Penmenvy wins FDA approval

UK pharma major GSK (LSE: GSK) late Friday announced that the US Food and Drug Administration (FDA) has approved Penmenvy (meningococcal groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 years.

The company noted that the vaccine targets five major serogroups of Neisseria meningitidis (A, B, C, W, and Y) which commonly cause invasive meningococcal disease (IMD).

This approval marks a significant advancement in meningococcal disease prevention, offering broad protection with a streamlined approach that could help improve vaccination rates among adolescents and young adults, said GSK.